| Drug General Information |
| Drug ID |
D0T2IX
|
| Former ID |
DNC007304
|
| Drug Name |
6-((1H-imidazol-1-yl)methyl)-2H-chromene-2-thione
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Target and Pathway |
| Target(s) |
Cytochrome P450 19 |
Target Info |
Inhibitor |
[1]
|
|---|
|
BioCyc Pathway
|
Superpathway of steroid hormone biosynthesis
|
|
Estradiol biosynthesis II
|
|
Estradiol biosynthesis I
|
|
KEGG Pathway
|
Steroid hormone biosynthesis
|
|
Metabolic pathways
|
|
Ovarian steroidogenesis
|
|
NetPath Pathway
|
FSH Signaling Pathway
|
|
PANTHER Pathway
|
Androgen/estrogene/progesterone biosynthesis
|
|
PathWhiz Pathway
|
Androgen and Estrogen Metabolism
|
|
Reactome
|
Endogenous sterols
|
|
WikiPathways
|
Metapathway biotransformation
|
|
Tryptophan metabolism
|
|
Oxidation by Cytochrome P450
|
|
Ovarian Infertility Genes
|
|
Metabolism of steroid hormones and vitamin D
|
|
FSH signaling pathway
|
|
Integrated Breast Cancer Pathway
|
|
Phase 1 - Functionalization of compounds
|
| References |
| REF 1 | J Med Chem. 2009 Jan 8;52(1):143-50.Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. |
|---|
